Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 24Breast Neoplasms, Male 2Triple Negative Breast Neoplasms 1Neoplasms 1Lung Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Cyclophosphamide 31Trastuzumab 30Paclitaxel 28Docetaxel 22Taxes 18Doxorubicin 18Radiotherapy 15Lapatinib 15Capecitabine 14Bevacizumab 13Tamoxifen 12Carboplatin 11Immunohistochemistry 9Filgrastim 9sargramostim 8Granulocyte-Macrophage Colony-Stimulating Factor 8Chemotherapy, Adjuvant 8Biopsy 8exemestane 7Vorinostat 7Magnetic Resonance Spectroscopy 7Letrozole 7Immunoenzyme Techniques 7Gemcitabine 7Anastrozole 7Albumin-Bound Paclitaxel 7pegfilgrastim 6Neoadjuvant Therapy 6Goserelin 6Fluorodeoxyglucose F18 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms, Male × Gefitinib × Breast × Clear all
NCT00086957 2017-02-27

Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer

City of Hope Medical Center

Phase 1/2 Completed
31 enrolled 10 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00024154 2013-01-24

Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
132 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡